These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 19593195)

  • 1. Clinical antipsychotic trials of intervention effectiveness study: a pragmatic trial?
    Manjunatha N; Saddichha S
    J Clin Psychopharmacol; 2009 Aug; 29(4):410-1. PubMed ID: 19593195
    [No Abstract]   [Full Text] [Related]  

  • 2. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). How to prescribe an APAP?].
    Dassa D; Lacambre M; Vacheron MN
    Encephale; 2009 Jan; Suppl 3():S109-13. PubMed ID: 19268179
    [No Abstract]   [Full Text] [Related]  

  • 3. The Clinical Antipsychotic Trials of Intervention Effectiveness: what did we learn?
    Boyd MA
    Arch Psychiatr Nurs; 2008 Feb; 22(1):56-8. PubMed ID: 18207059
    [No Abstract]   [Full Text] [Related]  

  • 4. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). How to make the decision to resort to an APAP)].
    Chéreau I; Gorwood P; Mouchabac S
    Encephale; 2009 Jan; Suppl 3():S97-100. PubMed ID: 19268186
    [No Abstract]   [Full Text] [Related]  

  • 5. Partition testing in dose-response studies with multiple endpoints.
    Liu Y; Hsu J; Ruberg S
    Pharm Stat; 2007; 6(3):181-92. PubMed ID: 17654696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). Current status of recommendations for treatment with an APAP].
    Buis C; Gourion D; Vaiva G
    Encephale; 2009 Jan; Suppl 3():S91-5. PubMed ID: 19268185
    [No Abstract]   [Full Text] [Related]  

  • 7. Activation induced by high-dose ziprasidone: a case report.
    Kaushik S; Maccabee N; Kaushik S; Lindenmayer JP
    J Clin Psychiatry; 2009 Sep; 70(9):1326-7. PubMed ID: 19818257
    [No Abstract]   [Full Text] [Related]  

  • 8. A continuous responder analysis from a long-term trial of duloxetine treatment for generalized anxiety disorder: implications for the randomized withdrawal relapse prevention study design.
    Llorca PM; Bodkin JA; Spann M; Ball SG; Russell JM; Ball SG
    J Clin Psychopharmacol; 2009 Feb; 29(1):96-7. PubMed ID: 19142122
    [No Abstract]   [Full Text] [Related]  

  • 9. Rhabdomyolysis following dose increase of clozapine and combination therapy with lithium.
    Tseng KC; Hwang TJ
    J Clin Psychopharmacol; 2009 Aug; 29(4):398-9. PubMed ID: 19593187
    [No Abstract]   [Full Text] [Related]  

  • 10. Atypical antipsychotics in the treatment of delirium.
    Peritogiannis V; Stefanou E; Lixouriotis C; Gkogkos C; Rizos DV
    Psychiatry Clin Neurosci; 2009 Oct; 63(5):623-31. PubMed ID: 19674385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A chemotherapeutic alternative to the antianxiety agents for the extended treatment of psychoneurosis.
    Lofft JG; Demars JP
    Dis Nerv Syst; 1974 Sep; 35(9):409-15. PubMed ID: 17894066
    [No Abstract]   [Full Text] [Related]  

  • 12. Response to Shen J, Kobak K, Zhao Y, et al. Use of remote centralized raters via live 2-way video ina multicenter clinical trial for schizophrenia. (J Clin Psychopharmacol. 2008;28:691-693).
    Grunze HC; Höschl C; Montgomery SA; Sartorius N; Vieta E
    J Clin Psychopharmacol; 2009 Aug; 29(4):409; author reply 409-10. PubMed ID: 19593194
    [No Abstract]   [Full Text] [Related]  

  • 13. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). Position of Canadian psychiatry].
    Stip E
    Encephale; 2009 Jan; Suppl 3():S115-8. PubMed ID: 19268180
    [No Abstract]   [Full Text] [Related]  

  • 14. Introduction: evaluating the evidence: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and beyond.
    Nasrallah HA
    J Clin Psychiatry; 2007; 68 Suppl 1():3-4. PubMed ID: 17286521
    [No Abstract]   [Full Text] [Related]  

  • 15. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
    Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG;
    Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applications of the AMP/AMDP-System to drug trials.
    Mod Probl Pharmacopsychiatry; 1983; 20():204-10. PubMed ID: 6137767
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia.
    Lee KU; Jeon YW; Lee HK; Jun TY
    Hum Psychopharmacol; 2009 Aug; 24(6):447-52. PubMed ID: 19606454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rating rater improvement: a method for estimating increased effect size and reduction of clinical trial costs.
    Cogger KO
    J Clin Psychopharmacol; 2007 Aug; 27(4):418-20. PubMed ID: 17632240
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical trials in neonates: a therapeutic imperative.
    Ward RM; Kern SE
    Clin Pharmacol Ther; 2009 Dec; 86(6):585-7. PubMed ID: 19915600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The factor structure of clinical symptoms in mixed and manic episodes prior to and after antipsychotic treatment.
    Harvey PD; Endicott JM; Loebel AD
    Bipolar Disord; 2008 Dec; 10(8):900-6. PubMed ID: 19594505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.